

CORRECTION



Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions

C. -R Pradeep, A. Zeisel, W. J. Köstler, M. Lauriola, J. Jacob-Hirsch, B. Haibe-Kains, N. Amariglio, N. Ben-Chetrit, A. Emde, I. Solomonov, G. Neufeld, M. Piccart, I. Sagi, C. Sotiriou, G. Rechavi, E. Domany, C. Desmedt and Y. Yarden

© The Author(s), under exclusive licence to Springer Nature Limited 2024

Oncogene (2024) 43:1317; <https://doi.org/10.1038/s41388-024-02990-w>

Correction to: *Oncogene* <https://doi.org/10.1038/onc.2011.547>, published online 05 December 2011

It was brought to our attention that one of the images shown in Figure 6c (MCF10A-HER2 cells treated with EGF plus GM6001) was inadvertently presented in one of the images of Figure 1a (MCF10A-HER2 cells treated with EGF). We have corrected this unintentional error and present below the correct form of Figure 1a. This image correction did not change the quantification associated with the image.

Figure 1 HER2 delays intraluminal apoptosis and GFs induce invasive arm formation by MCF10A spheroids grown in extracellular matrix. (a) MCF10A and MCF10A/HER2 monolayers (50,000 cells) were plated on Matrigel-coated Transwell chambers and incubated for 12 h in the presence or absence of EGF (20 ng/ml). Thereafter, the opposite face of the Transwell filter was stained using crystal violet. The lower part presents quantification of the number of cells that migrated to the other side of the filter.

